On behalf of the GMMMG Clinical Reference Group, we now seek comments on the actions proposed at the March 2026 CRG meeting. Actions in this consultation include:
- Carbidopa / entacapone / levodopa tablets – add Sastravi and Stanek to formulary
- Methylphenidate for narcolepsy – AMBER
- Budesonide for primary IgA nephropathy – update formulary to reflect TA1128
- Obinutuzumab for lupus nephritis – RED
- Dupilumab for severe chronic rhinosinusitis with nasal polyps – RED
- Discontinued products to be removed from formulary:
- FreeStyle Libre 3 sensor (replaced by FSL3+)
- Peanut allergy immunotherapy (Palforzia)
- Sotrovimab for COVID-19
All links to NICE clinical guidelines and MHRA drug safety updates will be added to formulary as appropriate.
This consultation will run for six weeks and closes at 5pm on Thursday 30th April 2026. To take part, visit the consultations page.